Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?
Carlo Alberto Maronese, John R Ingram, Angelo Valerio Marzano
Abstract
As the landscape for hidradenitis suppurativa (HS) medical treatment is rapidly expanding, seemingly taking the same steps that marked the evolution of psoriasis management, upcoming agents still do not appear to offer complete disease control. Better control of severe cases of HS refractory to biologic monotherapy may require investigation of pathogenesis-driven, combination regimens sooner rather than later.
Topics & Concepts
Hidradenitis suppurativaMedicinePsoriasisRefractory (planetary science)DermatologyPathogenesisDiseaseIntensive care medicineInternal medicineBiologyAstrobiologyHidradenitis Suppurativa and TreatmentsColorectal and Anal CarcinomasMicroscopic Colitis